Discussion We examined the experiences of patients with obesity or T2D attending medical weight management or community diabetes service respectively, who were prescribed a GLP-1 receptor agonist, with respect to changes in their mental health including eating behaviours
These findings highlight the potential clinical importance of achieving and maintaining weight loss after GLP-1-based treatment initiation. Meeting: European Congress on Obesity 2026 (ECO2026) Never miss a breakthrough: Join the SciTechDaily newsletter
declares research contracts with Daiichi Sankyo, Eleor, Kaleido Biosciences, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Sutro Biopharma, Tollys, and VASCage
But without insurance, these drugs are prohibitively expensive, especially the name-brand ones
BN inhibited meal intake at higher doses for more than 4 hours, leading to weight loss in ob/ob mice after about two weeks of treatment
For an unlicensed investigational compound such as retatrutide, no such validated stability data exist